Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 14, 2009, Pages 3783-3786

  Kasper, Amanda C ^a   Moon, Eui Jung ^b   Hu, Xiangqian ^a   Park, Yongho ^a   Wooten, Ceshea M ^a   Kim, Hyoungsu ^a   Yang, Weitao ^a   Dewhirst, Mark W ^b   Hong, Jiyong ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

2,3 cis 3,4 trans 4,5 cis Tetrahydrofuran; 2,3 cis 3,4 trans 4,5 trans Tetrahydrofuran; 2,3 trans 3,4 trans 4,5 trans Tetrahydrofuran; Conformation activity relationship; Hypoxia; Hypoxia inducible factor 1; Manassantin A; Tetrahydrofuran analogue; Tetrahydrofuran configuration; Vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MANASSANTIN A; TETRAHYDROFURAN DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL SURVIVAL; CELL TYPE; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG CONFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYPOXIA; IC 50; INHIBITION KINETICS; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ANIMALS; CELL LINE; FURANS; HYPOXIA-INDUCIBLE FACTOR 1; LIGNANS; MICE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67649644629     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.071     Document Type: Article

References (40)

1. Semenza G.L. Nat. Rev. Cancer 56 (2003) 721
2. Bertout J.A., Patel S.A., and Simon M.C. Nat. Rev. Cancer 12 (2008) 967
3. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 5510
4. Flamme I., Frolich T., and Risau W. Mol. Pharmacol. 70 (2006) 1469
5. Lisy K., and Peet D.J. Cell Death Differ. 15 (2008) 642
6. Vaupel P. Semin. Radiat. Oncol. 14 (2004) 198
7. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Int. J. Radiat. Oncol. Biol. Phys. 38 (1997) 285
8. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Cancer Res. 56 (1996) 4509
9. Semenza G.L. Drug Discovery Today 12 (2007) 853
10. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., and Semenza G.L. Cancer Res. 61 (2001) 2911
11. Koukourakis M.I., Giatromanolaki A., Sivridis E., Simopoulos C., Turley H., Talks K., Gatter K.C., and Harris A.L. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 1192
12. Kung A.L., Wang S., Klco J.M., Kaelin W.G., and Livingston D.M. Nat. Med. 6 (2002) 1335
13. Zhang X., Kon T., Wang H., Li F., Huang Q., Rabbani Z.N., Kirkpatrick J.P., Vujaskovic Z., Dewhirst M.W., and Li C.Y. Cancer Res. 64 (2004) 8139
14. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Cancer Cell 5 (2004) 429
15. Giaccia A., Siim B.G., and Johnson R.S. Nat. Rev. Drug Disc. 10 (2003) 803
16. Lin X., David C.A., Donnelly J.B., Michaelides M., Chandel N.S., Huang X., Warrior U., Weinberg F., Tormos K.V., Fesik S.W., and Shen Y. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 174
17. Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., Rey S., Hammers H., Chang D., Pili R., Dang C.V., Liu J.O., and Semenza G.L. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 19579
18. Rao K.V., and Alvarez F.M. Tetrahedron Lett. 24 (1983) 4947
19. Hodges T.W., Hossain C.F., Kim Y.-P., Zhou Y.-D., and Nagle D.G. J. Nat. Prod. 67 (2004) 767
20. Hossain C.F., Kim Y.-P., Baerson S.R., Zhang L., Bruick R.K., Mohammed K.A., Agarwal A.K., Nagle D.G., and Zhou Y.-D. Biochem. Biophys. Res. Commun. 333 (2005) 1026
21. Moeller B.J., Dreher M.R., Rabbani Z.N., Schroeder T., Cao Y., Li C.Y., and Dewhirst M.W. Cancer Cell 8 (2005) 99
22. Moeller B.J., Batinic-Haberle I., Spasojevic I., Rabbani Z.N., Anscher M.S., Vujaskovic Z., and Dewhirst M.W. Int. J. Radiat. Oncol. Biol. Phys. 63 (2005) 545
23. Viola R.J., Provenzale J.M., Li F., Li C.Y., Yuan H., Tashjian J., and Dewhirst M.W. Am. J. Roentgenol. 191 (2008) 1779
24. Tarnawski A.S., and Jones M.K. J. Mol. Med. 81 (2003) 627
25. Macpherson G.R., and Figg W.D. Cancer Biol. Ther. 3 (2004) 503
26. Dang D.T., Chen F., Gardner L.B., Cummins J.M., Rago C., Bunz F., Kantsevoy S.V., and Dang L.H. Cancer Res. 66 (2006) 1684
27. Kim H., Wooten C.M., Park Y., and Hong J. Org. Lett. 9 (2007) 3965
28. Kim H., Baker J.B., Lee S.-U., Park Y., Bolduc K.L., Park H.-B., Dickens M.G., Lee D.-S., Kim Y.-C., Kim S.H., and Hong J. J. Am. Chem. Soc. 131 (2009) 3192
29. Kim H., Kasper A.C., Moon E.J., Park Y., Wooten C.M., Dewhirst M.W., and Hong J. Org. Lett. 11 (2009) 89
30. Wang G.L., and Semenza G.L. Blood 82 (1993) 3610
31. + 732.4].
32. + 732.3510].
33. Li F., Sonveaux P., Rabbani Z.N., Liu S., Yan B., Huang Q., Vujaskovic Z., Dewhirst M.W., and Li C.Y. Mol. Cell 26 (2007) 63
34. To avoid any unnecessary complications and/or exaggeration by the flexible side chains, truncated structures of 1, 11, and 13 were used instead of the full structures. Initial geometries were determined by conformational search based on molecular mechanics (MMFF).
35. Lee C., Yang W., and Parr R.G. Phys. Rev. B 37 (1988) 785
36. Vosko S., Wilk L., and Nusair M. Can. J. Phys. 58 (1980) 1200
37. Becke A.D. Phys. Rev. A 38 (1988) 3098
38. Becke A.D. J. Chem. Phys. 98 (1993) 5648
39. Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Montgomery Jr. J.A., Vreven T., Kudin K.N., Burant J.C., et al. Gaussian 03, Revision D.02 (2004), Gaussian, Wallingford, CT
40. Optimization of the full structures of 1, 11, and 13 using density functional theory (B3LYP) at the 6-31G* level provided the same conclusion (see Supplementary data for details).